Pharsight

Abbvie Endocrine Inc patents expiration

1. Lupron Depot patents expiration

LUPRON DEPOT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5643607 ABBVIE ENDOCRINE INC Prolonged release microcapsules
Jan, 2013

(11 years ago)

US5480656 ABBVIE ENDOCRINE INC Prolonged release microcapsules
Jan, 2013

(11 years ago)

US5716640 ABBVIE ENDOCRINE INC Method of producing sustained-release microcapsules
Sep, 2013

(10 years ago)

US5575987 ABBVIE ENDOCRINE INC Method of producing sustained-release microcapsules
Sep, 2013

(10 years ago)

US5631020 ABBVIE ENDOCRINE INC Method for producing microcapsule
May, 2014

(9 years ago)

US5631021 ABBVIE ENDOCRINE INC Method for producing microcapsule
May, 2014

(9 years ago)

US6036976 ABBVIE ENDOCRINE INC Sustained release microspheres and preparation thereof
Dec, 2016

(7 years ago)

US7429559 ABBVIE ENDOCRINE INC Controlled release composition and method of producing the same
Jan, 2019

(5 years ago)

US8815801 ABBVIE ENDOCRINE INC Controlled release composition and method of producing the same
Jun, 2022

(1 year, 9 months ago)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Jun 17, 2014
New Dosing Schedule(D-132) Jun 17, 2014

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

How can I launch a generic of LUPRON DEPOT before it's drug patent expiration?
More Information on Dosage

LUPRON DEPOT family patents

Family Patents

2. Lupron Depot-ped Kit patents expiration

LUPRON DEPOT-PED KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5480656 ABBVIE ENDOCRINE INC Prolonged release microcapsules
Jan, 2013

(11 years ago)

US5643607 ABBVIE ENDOCRINE INC Prolonged release microcapsules
Jan, 2013

(11 years ago)

US5716640 ABBVIE ENDOCRINE INC Method of producing sustained-release microcapsules
Sep, 2013

(10 years ago)

US5575987 ABBVIE ENDOCRINE INC Method of producing sustained-release microcapsules
Sep, 2013

(10 years ago)

US5631020 ABBVIE ENDOCRINE INC Method for producing microcapsule
May, 2014

(9 years ago)

US6036976 ABBVIE ENDOCRINE INC Sustained release microspheres and preparation thereof
Dec, 2016

(7 years ago)

US9617303 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Mar, 2028

(3 years from now)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Apr 14, 2026
M(M-107) Oct 08, 2014
New Product(NP) Aug 15, 2014

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 16 April, 1993

Treatment: Treatment of pediatric patients with central precocious puberty

Dosage: POWDER;INTRAMUSCULAR

More Information on Dosage

LUPRON DEPOT-PED KIT family patents

Family Patents